Current Procedural Terminology (CPT®) allows code assignment and publication for vaccines that are pending approval by the US Food and Drug Administration (FDA). Publication of codes prior to the products reaching the US market avoids any period where the vaccine is provided but no code is available for reporting. A lightning bolt symbol (<img>) is appended to codes for vaccines that are pending FDA approval. When the CPT Editorial Panel is advised that a vaccine has received FDA approval, the lightning bolt symbol is removed in online documents and from the next CPT manual. Several codes for vaccines that included a lightning bolt symbol in 2020 will appear in CPT 2021 without the symbol.

Newly approved vaccine products for pediatric immunization and the codes for reporting them are as follows:

Dengvaxia (Sanofi-Pasteur), a tetravalent, live-attenuated dengue virus vaccine, was approved in May 2019 for use in patients...

You do not currently have access to this content.